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Key Points: 
 
1) Candidate gene and genome-wide association studies (GWAS) in well 
characterized cases have delineated molecular mechanisms underlying 
development of DILI. 
2) Distinct physicochemical properties of the peptide-binding grooves of HLA 
molecules determine the specificity of drug-antigens presented and resultant 
activation of drug-specific T cells. 
3) Carriage of single nucleotide polymorphisms (SNPs) in particular genes and 
Human Leucocyte Antigen (HLA) alleles can be utilized as tests to support or 
refute the diagnosis of DILI. 
4) Different HLA alleles associated with DILI and autoimmune hepatitis (AIH) can be 
used to distinguish these two conditions with similar manifestations. 
5) Evidence does not support treatment of DILI with corticosteroids routinely. 
6) In cases of drug-induced AIH treated with corticosteroid therapy, withdrawal of 
immunosuppressive therapy does not lead to relapse of liver injury.  
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Summary 
A number of drug-specific and host-related factors contribute to the development of 
drug-induced liver injury (DILI). Investigations focused on genetic susceptibility to 
DILI have advanced our understanding of the pathogenesis of this rare, yet 
potentially life-threatening adverse reaction. Candidate gene studies involving well-
characterized patients with DILI and drug-exposed controls have identified single 
nucleotide polymorphisms (SNPs) affecting the metabolism and clearance of specific 
drugs and hence, influencing individual’s susceptibility to DILI. On the other hand, a 
series of genome-wide association studies (GWASs) have revealed a number of 
Human Leucocyte Antigen (HLA) alleles that are associated with DILI secondary to 
compounds with dissimilar chemical structures, highlighting the role of adaptive 
immune responses in the development of liver damage. These risk alleles, such as 
HLA-DRB1*15:02 illustrated by the example presented in the clinical vignette, 
determine the physicochemical properties of the peptide-binding grooves of the HLA 
molecules and increase the likelihood of DILI in a susceptible individual by altering 
the nature or the magnitude of immune-mediated liver injury. Associations of HLA 
alleles with DILI secondary to specific drugs can be translated into genetic tests, and 
when performed selectively, can improve the accuracy of diagnosis of DILI as well as 
assist in identifying the correct causal agent when the event could be attributed to 
more than one drug.  
 
Clinical vignette 
A 21-year old woman was admitted with a 2-week history of painless jaundice, 
fatigue and anorexia having been previously fit and well. One month prior to 
presentation, the patient had taken a 5-day course of amoxicillin-clavulanic acid for 
an infected skin cyst. She was otherwise on the oral contraceptive pill only and 
reported minimal alcohol intake. On examination, she was deeply jaundiced, but, 
alert and oriented with no asterixis. She had no stigmata of chronic liver disease, but 
hepatomegaly extending 3 cm from below the right subcostal margin was evident. 
Investigations showed a white cell count of 13.4 x109/L (normal 3.6-9.3), hemoglobin 
was 11.8 g/dL (normal 11-15), platelet count of 356 x109/L (normal 170-420), sodium 
was 138 mmol/L (normal 134-144), potassium was 3.5 mmol/L (normal 3.5-5.0), 
creatinine 32 µmol/L (normal 40-75), albumin 30 g/L (normal 35-48), alanine 
transaminase (ALT) 707 IU/L (normal 15-54), alkaline phosphatase 151 IU/L (normal 
30-130), bilirubin 384 µmol/L (normal 7-31) and prothrombin time 27.2 s (normal 
11.7-14). Screening for hepatitis A, B, C, E, Epstein-Barr virus, cytomegalovirus and 
autoimmune hepatitis was negative. Tests for anti-smooth muscle (ASM), antinuclear 
(ANA), and anti-liver-kidney microsomal-1 (LKM) antibodies were negative; 
immunoglobins levels and caeruloplasmin levels were normal. Liver ultrasonography 
demonstrated a liver of normal contour with no biliary dilatation, a normal spleen size 
and patent vessels. Liver biopsy revealed severe portal interface hepatitis with 
lobular inflammation and scant plasma cells.  
Her clinical condition deteriorated in the following days with prothrombin time 
and bilirubin rising to 56.6 s and 470 µmol/L, respectively. At follow-up after 11 days 
her ALT was 1931 IU/L. She developed grade 2 hepatic encephalopathy 14 days 
after presentation, and was listed for a super-urgent liver transplant. HLA typing was 
performed as a part of preparatory investigations and showed the patient carried the 
HLA haplotype HLA-DRB1*15:02-DQB1*06:01. Following orthotopic transplantation 
of a deceased donor graft her explant histology revealed severe ongoing hepatitis 
with multi-acinar necrosis (Fig. 1 A and B).  
This case raised a number of important questions about the diagnosis of DILI 
and tools available for clinicians to make best decisions for patient care: 
How is the diagnosis of DILI made? 
What are the risk factors including genetic risk factors? 
What are the mechanisms of liver injury? 
Are there prognostic factors that can be considered? 
What are the potential therapeutic options? 
This grand round will try to explore these questions and describe the 
pathophysiology, diagnostic and prognostic biomarkers, clinical management and 
discuss areas of uncertainty. 
 
Clinical-molecular pathological correlation 
The HLA DRB1*15:01-DQB1*06:02 haplotype common in European 
populations is a well-established risk factor for increased susceptibility to DILI on 
exposure to amoxicillin-clavulanic acid [1]. The patient described in the clinical 
vignette was of South Asian (Indian) origin and carried the HLA haplotype HLA-
DRB1*15:02-DQB1*06:01. HLA-DRB1*15:02 is present in only 0.7% of the 
Caucasian population while its prevalence is 8% in Taiwan and Japan [2, 3] and 
13%-18% among Asians [4, 5].  
The differences between protein products of different HLA-DRB alleles are 
concentrated in the peptide-binding groove of the MHC molecule. Variations in the 
physicochemical properties of the peptide-binding groove determine the specificity of 
the drug-metabolite-protein product that is presented by the HLA molecules, a key 
step in the immune mechanism mediating the DILI that ensues. The only difference 
in the 266 amino acid sequence of HLA DRB1*15:01 and DRB1*15:02 is at position 
86 located in the peptide binding groove of the molecule (Fig. 2). Most people carry 
DNA sequence encoding a glycine (Gly) or Valine (Val) at this position. As these 
amino acids have similar physiochemical properties, this variation is unlikely to 
mediate major functional differences relevant to antigen presentation. Residue 86 of 
the HLA-DRB1*15:01 -chain is integral to the formation of the P1 binding pocket for 
peptide antigens [6] as illustrated in Fig. 2A and C (PDB 1BX2, visualised in PyMol 
[7]). Comparison of a Val86Gly structural homology model representative of HLA-
DRB1*15:02, derived from the solved structure of HLA-DRB1*15:01 ([8], Fig. 2B and 
D), shows broadly equivalent electrostatic potential of pocket P1 for both alleles ([9, 
10], Fig 2E and F, [6]). This suggests that most DRB P1 pockets have an overall 
neutral charge which is also minimally affected by Val86Gly variation. Therefore, 
DRB1*15:02-DQB1*06:01 would be predicted to have similar association with 
amoxicillin-clavulanic acid DILI in Asian populations as described for DRB1*15:01-
DQB1*06:02 in Caucasians [1]. 
Members of the DRB1*15 family of alleles, have been associated with 
immune-allergic reactions following exposure to a variety of potential toxins and 
xenobiotic agents including DILI due to nitrofurantoin and halothane [11, 12]. DRB1 
is a HLA class II gene but genes from the closely related HLA class I family, 
especially HLA-B, are also relevant to adverse drug reactions. Association of HLA-
B*57:01 with serious cutaneous hypersensitivity secondary to abacavir, an anti-
retroviral agent is the most well investigated example of a genetic risk factor for an 
adverse drug reaction with a negative predictive value of 100% and positive 
predictive value of 48% [13]. Therefore, HLA-B*57:01 genotyping prior to abacavir 
prescription has been mandated by the Food and Drug Administration as well as the 
European Medicine Agency. 
  
How is the diagnosis of DILI made? 
Accurate diagnosis is the key step in the management of DILI, as identifying 
and withdrawing the offending agent is a critical intervention; it is equally important to 
consider the fact that cessation of an effective medication incorrectly (by wrongly 
attributing DILI to a particular drug) has implications for the patient, as treatment of 
the underlying condition needs to be revised. In addition, attributing the clinical 
manifestations to DILI inaccurately means that the correct underlying diagnosis such 
as autoimmune hepatitis or biliary obstruction is missed, with long-term adverse 
consequences to the patient.   
Clinicians’ awareness of the association of a particular drug with a pattern of 
manifestation is an important first step in the process of diagnosis. However, barring 
a few exceptions such as ‘acute fatty liver’-associated drugs such as valproate, 
stavudine, zalcitabine or didanosine, the vast majority of DILI do not have sufficiently 
distinct ‘signature’ patterns that are consistently recognisable. Considering the fact 
that over 350 drugs have been convincingly linked to DILI [14] , many clinicians 
access dedicated websites such as LiverTox [15] as an up to date source of 
information.  A systematic evaluation of the circumstantial evidence that supports the 
diagnosis of DILI and exclusion of alternative aetiology that could lead to similar 
pattern of liver injury has been termed ‘causality assessment’. One such method 
involves the use of the ‘Council for International Organizations of Medical Sciences 
(CIOMS) Scale’ which includes a weighted scoring of an event according to distinct 
domains related to the temporal relationship between exposure to a particular drug 
and the liver injury, exclusion of alternative, non-drug related aetiologies, exposure to 
other medications that could explain DILI, risk factors for the adverse hepatic 
reaction, evidence in the literature regarding DILI from drug in question and 
response to re-exposure to the medication. Causality methods such as the CIOMS 
scale provide a degree of objectivity and consistency in the process of diagnosis of 
DILI [16-18]. However, the tool has a number of limitations; it recommends an 
exhaustive list of exclusions making the diagnosis expensive and thus causality 
assessments are not widely used in clinical practice. So overall, the accuracy of 
clinical diagnosis of DILI remains low; a recent prospective study based in a 
secondary care hospital setting demonstrated that only 12% of drug-related liver 
enzyme elevations of more than 3 times upper limit of normal were identified by the 
clinical team in charge of the care for the patient [19].   
Over the past decade, candidate gene studies, initially, and GWAS, more 
recently, have identified several genetic factors associated with DILI (Table 1) 
(reviewed by [20-22]). While associations with single nucleotide polymorphismas 
(SNPs) in genes involved in drug metabolism and excretion have been drug specific, 
some HLA alleles have been associated with DILI from a number of drugs of varying 
structure. There are over 15 currently used drugs where HLA genotype or haplotype 
increases the susceptibility to DILI and, as demonstrated by high relative risks, some 
of these associations are strong [23-26]. Rarity of occurrence of DILI in relationship 
with a given drug means that many of these HLA alleles have a negative predictive 
value of >95%. Consequently, genetic tests have been used to exclude the 
diagnosis of DILI or identify the right aetiological agent when more than one potential 
medication could have caused DILI [27, 28].In addition to the above, HLA genotyping 
in combination with other serological markers could strengthen the diagnosis of DILI.  
There are substantial overlaps between DILI and autoimmune hepatitis (AIH), 
so that 9% of DILI cases are indistinguishable from AIH [29]. On the other hand, 9% 
of AIH occurrences are considered drug-induced, highlighting the challenge in 
establishing the diagnosis of both clinical scenarios [30]. In routine clinical practice, a 
combination of clinical features, serological, histological parameters as well as 
genetic tests are considered in reaching the diagnosis of idiopathic AIH as none of 
the individual features are pathognomonic [31]. In a recent nationwide cohort 
involving 1267 patients with AIH, only 65% of those meeting the original International 
AIH Group criteria also met a simplified International AIH score [32]. HLA genotyping 
in particular has been included within the original International AIH Group criteria 
[33]. Therefore, when a patient suspected to have DILI also tests positive for liver 
specific auto-antibodies (ANA, anti-SMA, anti-LKM) or has raised immunoglobulins 
[34], carriage of specific HLA alleles in the patient would support the diagnosis of 
AIH (DRB1*03:01 and *04:01) or DILI (risk allele for specific drug in question).  
Table 2 lists diagnostic tests useful for diagnosis of DILI and the frequencies 
for specific HLA genes of interest in the reference population and in cases of DILI 
due to common drugs. These data provide an indication of the positive yield of the 
genetic tests in cases of DILI compared to their frequency in the reference 
population. For example, if applied in clinical practice, genotyping for HLA-
DRB1*15:01 when amoxicillin-clavulanic acid DILI is suspected, HLA-B*57:01 in 
suspected flucloxacillin-induced DILI and HLA-B*35:02 in a possible minocycline 
DILI case would have similar performance characteristics to anti-nuclear antibody 
(ANA), immunoglobulin G estimation and anti-liver kidney microsomal (LKM) 
antibody test, respectively in a case of suspected AIH. Considering the importance of 
clinical decision-making, such as permanent withdrawal of an effective medication in 
a patient and/or initiation of long-term immunosuppressive regimen, incorporating 
genetic tests into diagnostic armamentarium is justified and would increase the 
accuracy and confidence in the diagnosis. 
 
What are the risk factors including genetic risk factors? 
A number of drug-related and host factors increase an individual’s 
susceptibility to DILI as well as reduce the likelihood of the development of clinically 
significant adverse reaction. Drugs with a daily dose of 50 mg or higher are more 
likely to be associated with DILI and there is also a significant relationship between 
daily dose and reports of liver failure, liver transplantation, as well as death caused 
by DILI [35]. In addition, compounds with >50% hepatic metabolism are more likely 
to be associated with ALT >3 times the upper limit of normal, liver failure and fatal 
DILI [36]. Suggestion that lipophilicity of a compound, independently of other 
properties, may increase its hepatotoxic potential has recently been refuted [37, 38]. 
Drugs with dual potency as mitochondrial and bile salt export pump inhibitors are 
associated with severe human DILI [39]. 
Age may be a risk factor increasing susceptibility to DILI due to anti-
tuberculosis drugs and flucloxacillin [40, 41]. Chronic hepatitis B and C are also 
associated with increased risk of DILI from anti-HIV and anti-tuberculosis therapies 
[40, 42, 43]. In different ethnic groups, significantly different medications underlie 
DILI [44].  Trimethoprim/sulfamethoxazole, methyldopa and phenytoin are more 
often the cause of DILI among African-Americans, while amoxicillin-clavulanic acid is 
a causative agent in a higher proportion of Caucasians. In addition, severe 
cutaneous reactions, rates of hospitalisation, liver transplantation or liver-related 
deaths are more frequent among African–Americans, compared to Caucasians, after 
controlling for selected covariates [44] . As discussed previously, accumulating 
evidence over the past decade points consistently towards genetic factors being 
associated with the individual’s risk of developing liver injury on exposure to 
medications. 
 
What are the mechanisms of liver injury?  
It is generally believed that low molecular weight organic chemicals, such as 
drugs, are not immunogenic but may become so when bound to a macromolecule, 
such as a protein. Medications with a high daily therapeutic dose, those which 
predominantly undergo hepatic metabolism and biliary excretion are more frequently 
associated with severe DILI suggesting that formation and clearance of reactive 
metabolites, steps that are common for many compounds, are likely upstream 
events mediating liver injury. Consistent with this, SNPs in genes coding for drug-
metabolizing enzymes and transporters involved in the excretion of drug metabolites 
have been associated with increased susceptibility to DILI [21]. An increasing 
number of drugs are shown to be ‘haptens’, generating sensitizing molecules that 
are directly protein reactive and form covalent adducts in vivo [45-47]. The 
observation that the formation of reactive metabolites and covalent adducts are 
associated with exposure to the drug, even in the absence of clinically significant 
liver injury, indicates that, while upstream events are essential steps in the 
pathogenesis, they are not sufficient on their own to lead to severe DILI. Rather, a 
subclinical event may release drug-altered peptide to be taken up by antigen 
presenting cells or stimulate production of ‘danger signals’, hence triggering a 
pathogenic adaptive immune response [48]. 
In the past 8 years, GWASs have identified several HLA alleles and 
haplotypes as strong risk factors associated with DILI (reviewed in [20]). A relatively 
small number of HLA class I and class II alleles are associated with DILI from a wide 
variety of structurally dissimilar drugs. In addition, examples of HLA alleles that 
increase susceptibility to specific drug-related liver injury while being protective of 
DILI from others supports the ‘hapten hypothesis’. The majority of these alleles vary 
in the amino acid residues that determine the physicochemical properties of the 
peptide-binding grooves of the HLA molecules they encode. Presentation of drug- or 
metabolite-altered peptide in the peptide-binding groove of particular HLA molecules 
is a key step in the activation of drug-specific T cells and immune-mediated injury 
manifesting as DILI. While HLA class I molecules can be associated with cytotoxic 
CD8+ T cell-mediated hepatocyte injury, HLA class II molecules invoke interaction 
between antigen presenting cells and CD4+ T cells, leading to inflammation and liver 
injury (Fig. 2G). With regards to flucloxacillin and amoxicillin-clavulanic acid-induced 
DILI, experimental evidence supports the ‘hapten mechanism’ where MHC class II 
and I restricted CD4+ and CD8+ clones are activated by a drug-derived antigen [49, 
50].  
Considering that the structure of drugs are often designed to facilitate binding 
to specific receptors, some compounds or their metabolites may bind directly to HLA 
molecules or T cell receptors. Such ‘pharmacological interaction’ (p-i concept) may 
trigger activation and proliferation of T cells leading to immune-mediated liver injury 
[51]. More recently, some drugs have been shown to occupy the peptide-binding 
groove of HLA molecules, hence altering the repertoire of peptides (altered peptide 
repertoire model) that can bind to a particular HLA protein [52, 53]. This permits 
interaction between self-peptides and HLA molecules leading to immune-mediated 
DILI. 
 
Prognostic markers  
A number of serum/ plasma biomarkers are being investigated with a view to 
develop tests that can assist in identifying patients with DILI who are likely to 
progress to acute liver failure or develop chronicity (reviewed in [54]). These include: 
organ-specific markers such as microRNA-122 associated with hepatocellular injury 
[55]; organelle-specific markers such as glutamate dehydrogenase, reflecting 
mitochondrial injury; mechanistic biomarkers such as cytokeratin-18 caspase-
cleaved fragment, and acetylated high mobility group box 1, reflecting apoptosis and 
necrosis, respectively; macrophage colony-stimulating factor receptor 1 associated 
with liver inflammation, and osteopontin associated with inflammatory cell activation 
and with liver regeneration due to activation of hepatic stem cells [54]. None of these 
have been validated in a well-characterized cohort of patients with idiosyncratic DILI 
and hence, they are not yet ready for clinical application. 
 
Areas of uncertainty 
While we apply the knowledge gained with regards to molecular mechanisms 
underlying the development of DILI in clinical practice, there is a compelling case of 
need for a technique that is capable of reflecting host genetic factors at the same 
time, recapitulating initial essential steps involving the metabolism and clearance of 
drugs as well as key events related to immune-mediated liver injury. Such a 
methodology could bring about a step change in investigations related to 
hepatotoxicity both in experimental and clinical settings. 
A recent publication describes a hepatotoxicity assay using monocyte-derived 
hepatocyte-like cells which show several donor-specific characteristics, reflect their 
monocyte/macrophage origin and potential innate immune function (expressing 
surface marker CD14 at low levels) [56]. In addition, these cells show activities of 
phase I and II metabolism as well as expressing transporter proteins involved in 
excretion of xenobiotics. Investigators describe the method of maintaining these cells 
in culture for a period of 42 days and these cells as having the expression patterns of 
hepatic enzymes that are similar to primary human hepatocytes maintained for 28 
days [57].   In a pilot study, in vitro testing using monocyte-derived hepatocyte-like 
cells derived from patients with acute liver injury was able to identify DILI with good 
performance characteristics. However, these cells would not reflect the key influence 
of the adaptive immune system in DILI pathogenesis and, hence, the application of 
this methodology in investigations related to hepatotoxicity from a wide range of 
drugs is uncertain. 
 
Management 
Early recognition of DILI and prompt withdrawal of the causal medication is 
crucial to minimise injury and its progression. In addition, measures such as clear 
documentation in the medical notes, information provided to the general practitioner, 
referring clinician or pharmacist and the patient to avoid inadvertent re-exposure to 
the causal medication are important. Although re-exposure does not always lead to 
recurrence of DILI, in 11% to 51% of cases when liver injury manifests (called 
positive rechallenge), [58] the consequences could be serious including mortality in 
2% to 13% of cases [59, 60]. So re-introduction of medication that has caused DILI 
in an individual should only be considered in discussion with the patient and under 
circumstances where benefits clearly outweigh the risks [58]. For example, when 
providing potentially life-saving cancer chemotherapy or when alternative 
medications to treat underlying conditions are not accessible or affordable as in 
cases of anti-tuberculosis treatment [61].  
Currently, treatment of DILI is limited to management of the patient’s 
symptoms such as itching [62]. There is not yet sufficient evidence to support the 
treatment of DILI with corticosteroids or ursodeoxycholic acid although these have 
been used in clinical practice and have been thought to enhance recovery [63]. In a 
cohort of patients with acute liver failure, there was no statistically significant 
improvement in overall survival in patients with DILI who received corticosteroids. 
Furthermore, in contrast, steroid use was associated with diminished survival in a 
subgroup of patients with a Model for Endstage Liver Disease (MELD) score of more 
than 40 [64]. However, initiation of corticosteroid treatment is justified in certain 
cases where drug-induced AIH is indistinguishable from the acute presentation of 
idiopathic AIH. Nevertheless, once the liver injury has resolved, as evidenced by 
normalization of liver enzymes, immunosuppression could be completely withdrawn 
with regular and close monitoring of patients. Long-term follow-up studies 
demonstrate that drug-induced AIH does not recur over a median follow up of 4 
years [65] with idiopathic AIH relapses in 63% of cases in 1 year and 75% of cases 
in 5 years [66]. Therefore, this is a reasonable approach considering that treatment 
of relapse of AIH is identical to that of its initial presentation.  
 
Potential Therapies 
With regards treatment of severe liver disease, administration of N-acetyl 
cysteine (NAC) significantly improved transplant-free survival in early stage non-
acetaminophen acute liver failure [67]. Transplant-free survival for DILI patients 
specifically was 58% (95% CI=33-83%) for those receiving NAC compared to 27% 
(95% CI=8-46%) receiving placebo. High-volume plasma exchange has also been 
shown to significantly improve outcome in acute liver failure in a prospective 
randomised multicentre trial of 182 patients [68]. Finally, emergency liver 
transplantation is an established procedure for refractory fulminant hepatic failure as 
in the case presented here. 
It is conceivable, from its crucial role in the pathogenesis, that interventions that 
modulate the adaptive immune response early in the course of DILI would arrest injury 
progression or assist in its resolution. Potential candidates include budesonide, based 
on its efficacy and lower rate of adverse effects in the treatment of autoimmune 
hepatitis [69], and nor-ursodeoxycholic acid, for its properties of reducing expression 
of MHC class II molecules on macrophages and inhibiting the proliferation of CD4+ T 
lymphocytes [70]. International consortia that have collaborated successfully in the last 
decade are well-placed to coordinate randomised clinical trials of treatments for DILI 
in the near future. 
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Figure Legends: 
 
Fig. 1. Liver explant histology in the DILI patient described. (A) Reticulin stained 
section x10 magnification. There is panacinar cell loss with occasional multiacinar 
collapse of the reticulin framework and regenerative-appearing islands of residual 
parenchyma. (B) H&E stained section x10 magnification. There is extensive bridging 
parenchymal collapse with haemorrhage into cell plates and residual islands of 
regenerative-appearing hepatocytes. The porto-septal areas contain a mild chronic 
inflammatory infiltrate, predominantly lymphocytic, and with florid ductular reaction 
adjacent to areas of hepatocyte loss. The findings are in keeping with a severe 
ongoing acute hepatitis with massive cell necrosis.  
 
Fig 2. Structure and electrostatic properties of the peptide binding groove of 
heterodimeric HLA-DRB1 alleles and their role in antigen presentation and 
stimulation of an immune response during DILI. (A) Structure of the HLA-
DRB1*15:01 (PDB 1BX2) peptide binding groove with valine 86 highlighted (space-
filled representation in lilac): the two different subunits that form the groove are 
coloured gold (β chain, HLA-DRB1) and claret (α chain, HLA-DRA) [8-10]. (B) 
Modelled structure of the HLA-DRB1*15:02 peptide binding groove [8-10] with 
glycine 86 highlighted (space-filled representation in lime green): the two different 
subunits that form the groove are coloured gold and claret [8-10]. (C) Surface 
representation of the pocket P1 region of HLA-DRB1*15:01 peptide binding groove 
with the position of valine 86 highlighted in lilac. (D) Surface representation of the 
pocket P1 region of HLA-DRB1*15:02 peptide binding groove with glycine at position 
86. (E) Molecular surface electrostatic potential of the HLA-DRB1*15:01 peptide 
binding groove highlighting the overall neutral charge of pocket P1 [8-10].Potentials 
are graded from -10kT/e, shown in blue, to +10kT/e in red, with neutral potentials (0 
kT/e) coloured white. (F) Molecular surface electrostatic potential of HLA-
DRB1*15:02 peptide binding groove highlighting the overall neutral charge of pocket 
P1 [8-10]. Potentials are graded from -10 kT/e, shown in blue, to +10 kT/e in red, 
with neutral potentials (0 kT/e) coloured white.  (G) Suggested role of HLA-DRB1 in 
presentation of drug-derived antigens by antigen presenting cells in DILI. Circulating 
drug or drug metabolite arising from hepatic metabolism, ‘hapten’, may be taken up 
by antigen presenting cells and processed as an antigen. The subsequent 
presentation of derived fragments in the peptide groove of the MHC class II HLA-
DRB1*15:01 or DRB1*15:02 has the potential to activate CD4+ T cells, co-stimulated 
by other factors released from damaged hepatocytes such as cytokines and danger-
signalling molecules. Thus stimulating immune responses associated with DILI. MHC 
II: major histocompatibility complex class II protein; APC: antigen-presenting cell; 
TCR: T cell receptor. 
 
  
 Table 1. Genetic susceptibility loci for DILI identified in GWAS and candidate 
gene studies.  
Association 
described:  
HLA allele 
Drug 
studied: 
Study type & cohort population  OR 
A*02:01 
rs2523822 
TRNAI25 
Amoxi-clav GWAS: 201 cases 532 P controls 
(European) [24] 
2.3 
A*30:02 Amoxi-clav CGS: 75 cases 885 P controls (European) [1] 6.7 
A*33  Tiopronin CGS: 14 cases, 472 T controls (Japanese) 
[71] 
NR 
A*33:01 Multiple  GWAS: 862 cases (21 terbinafine; 7 
fenofibrate; 5 ticlopidine cases) 10588 P 
controls (European) [26] 
40.5; 
58.7; 
163.1 
A*33:03 Ticlopidine CGS: 22 cases 85 T controls (Japanese) [72] 13 
B*08 Clometacin CGS: 30 cases (European) [73]  
B*18:01 Amoxi-clav CGS: 75 cases, 885 P control (European) [1] 2.9 
B*35:02 Minocycline GWAS: 25 cases, 10588 P controls 
(European) [25] 
29.6 
B*57:01 
rs2395029 HCP5 
Flucloxacillin CGS: 51 cases, 282 P controls  (European) 
[23] 
45 
B*57:01 Pazopanib CGS: 429 cases, 1761 T controls [74] 2.0 
B*57:02 Efavirenz + 
Anti-TB 
CGS: 46 cases, 46  controls (African) [75] 8.1 
B*57:03 Efavirenz + 
Anti-TB 
CGS: 46 cases, 46  controls (African) 26.8 
B*58:01 Nevirapine CGS: 57 cases, 111 T controls (South African) 
[76] 
 
DQA1*01:02 
protective 
Anti-TB CGS: 56 cases, 209 T controls (Indian) [77] 4 
DRB1*15:01-
DRB5*0101-
DQB1*06:02; 
DQB1*06:02 
rs9274407  
Amoxi-clav GWAS: 201 cases, 532 P controls (European) 
[24];                                           
CGS: (European) 35 cases, 300 P controls 
[78]; 22 cases 134 P controls [79]; 40 cases, 
140 P controls [80]; 75 cases, 885 P controls 
[1] 
3.1 
DRB1*01 Nevirapine CGS: 21 cases 133 T control (Caucasian) [81] NR 
DRB1*01:02 Nevirapine CGS: 57 cases 111 t controls (South African) 
[76] 
NR 
DRB1*07 
protectivea 
Amoxi-clav CGS: 40 cases, 140 P controls (European) 
[80] 
0.18 
DRB1*07: Ximelagatran GWAS: 74 cases, 130 T controls (European) 
[82] 
4.4 
DRB1*07:01 
(linkage with 
DQA1*02:01) 
Lapatinib GWAS: 37 cases, 286 T controls [83]; CGS: 
37 cases 1071 T controls. (European) [84]; 
GWAS: 34 cases, 810 T controls [85] 
NR 
DRB1*13 
protectivea 
Diclofenac CGS: (European) [86] NR 
DRB1*15:01  Lumiracoxib GWAS 41 cases, 176 T controls 
(International) [87] 
5 
DRB1*16:01-
DQB1*05:02 
Flupirtine  GWAS: 614 cases (6 flupirtine) 10588 P 
controls (European) [88] 
18.7 
DQB1*0201 Anti-TB CGS: 56 cases, 209 T controls (Indian) [77];  
GWAS: 59 cases, 111 T controls, 109 P 
controls (Indian): association not confirmed 
[89]  
1.9 
Association 
described: 
drug 
metabolism loci 
Drug 
studied: 
Study type & cohort population  OR 
ABCC2 
rs717620   
Diclofenac 
 
CGS: 24 cases, 48 T controls (European) [90] 5 
CYP2B6 *6  Efavirenz 
 
CGS: 41 cases, 160 T controls (South African) 
[91] 
NR 
CYP2B6 
rs7254579  
Ticlopidine 
 
CGS: 22 cases, 92 T controls (Japanese) [92] NR 
NAT2 slow 
acetylator 
alleles  
Isoniazid 
 
CGS: 26 cases, 101 P controls 
(European/Asian) [93];                                             
GWAS: 24 cases - association not 
confirmed [94] 
4.25 
UGT1A6/1A9  Tolcapone 
 
CGS: 135 cases, 234 T controls (European) 
[95];                                                                  
CGS: 2 cases (European) [96] 
NR 
UGT2B7*2   Diclofenac CGS: 24 cases, 48 T controls (European) [90];                                                           
GWAS: 34 cases - association partly 
confirmed [94] 
8.5 
Various other 
associations:  
Drug 
studied: 
Study type & cohort population  OR 
ALG10B 
rs6582630   
Flucloxacillin GWAS: 51 cases, 282 P controls  (European) 
[23] 
2.8 
C9orf82 
(CAAP1) 
rs10812428 
Flucloxacillin GWAS: 51 cases, 282 P controls  (European) 
[23] 
2.9 
ERN1 
rs199650082 
Efavirenz  GWAS: 21 cases, 234 T controls [97] (African) 18.2 
FAM65B intron 
rs10946737                                                                    
Rifapicin GWAS: 48 cases, 354 T controls [98];                  
CGS: 27 cases, 217 T controls (African) [98];                  
3.4 
lincRNA 
rs4842407 
Efavirenz + 
anti-TB 
GWAS: 42 cases, 292 T controls [97] (African) 5.4 
MCTP2 
rs4984390   
Flucloxacillin GWAS: 51 cases, 282 P controls  (European) 
[23] 
3.3 
OR5H2 
rs1497546  
Flucloxacillin GWAS: 51 cases, 282 P controls  (European) 
[23] 
6.6 
PPARG 
rs17036170   
Multiple 
(Diclofenac) 
GWAS: 783 cases (30 diclofenac) 3001 P 
controls (European) [94] 
11.3 
ST6GAL1 
rs10937275    
Flucloxacillin GWAS: 51 cases, 282 P controls  (European) 
[23] 
4.1 
Amoxi-clav: amoxicillin-clavulanic acid; OR: odds ratio; GWAS: genome-wide 
association study; CGS: candidate gene study; T: treated with same drug; P: 
population. Anti-TB drugs: isoniazid, rifampicin, pyrazinamide.  
 
  
Table 2. Summary of tests utilized for diagnosis of DILI and distinction from 
AIH and prevalence of variant alleles. 
Test: antibodies % positive in AIH cases 
[34] 
% positive in ‘normal’ 
population [99-101] 
ANA 1:60 68%-75%  15% (<40 ♀) - 24% (>40 ♀) 
Anti-SMA 52%-59% Up to 43% 
IgG >1600 mg/dl 86% 5%  
Anti-LKM 4%-20% 1% 
Test: HLA type % positive in DILI cases % positive in ‘normal’ 
population 
DRB1*15:01 57%-67% (Amoxicillin-
clavulanic acid) [1] 
15%-20% 
B*57:01 84%-87% (Flucloxacillin) 
[23] 
6% 
A*31:01 17% (Carbamazepine)*  2% 
DRB1*16:01-
DQB1*05:02 
25% (Flupirtine) [88] 1% 
A*33:01 80% (Ticlopidine), 
50% (Methyldopa), 
50% (Enalapril), 
43% (Fenofibrate), 
43% (Terbinafine), 
40% (Sertraline), 
20% (Erythrmycin), [26] 
1% 
B*35:02 16% (Minocycline) [25] 0.6% 
DILI: drug-induced liver injury; AIH: autoimmune hepatitis; ANA: antinuclear 
antibodies; SMA smooth muscle antibodies: LKM: liver-kidney microsome-1 
antibodies. * Nicoletti, unpublished. 
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